As IDO catalyzes the conversion of tryptophan into inhibitory metabolites that inhibit T-cell activity, IDO inhibitors were noted to enhance the efficacy of CD19-CAR-T-cell therapy in a xenograft lymphoma model [180]. The gene discussed is CD19; the disease is lymphoma.